Acurx Pharmaceuticals Inc. (NASDAQ:ACXP) shares are pulling back in premarket trading Thursday after the late-stage biopharmaceutical company rallied 107.93% to close sharply higher in Wednesday's session.

Overbought Signals Trigger Pullback

Technical indicators suggest the rally hit a ceiling on Wednesday. The ACXP Relative Strength Index (RSI) surged to the high 80s.

The stock's recent volatility follows a clinical update released Monday. Acurx Pharmaceuticals announced a new trial for ibezapolstat targeting patients with recurrent C. difficile infection (rCDI). The company cited a 96% clinical cure rate from Phase 2 data for the antibiotic candidate and said enrollment for the new study will begin in the fourth quarter.

Focus now shifts to the company's financial results, with Acurx Pharmaceuticals scheduled to report fourth-quarter 2025 earnings on Friday.

The loss per share is estimated at $1.00, compared with a $3.40 loss per share a year earlier.

Strategic Funding and FDA Status

The company is advancing into Phase 3 international studies, subject to funding. Ibezapolstat currently holds Food and Drug Administration Fast Track and Qualified Infectious Disease Product designations.

Technical Analysis

ACXP is trading 162.5% above its 20-day SMA and 48.3% above its 100-day SMA, showing a powerful short-term extension even as the longer-term trend is still working to repair itself.

Shares are down 35.16% over the past 12 months and, within the $1.33 to $21.00 52-week range, the stock is positioned closer to its lows than its highs.

• Key Resistance: $5.50
• Key Support: $5.00

ACXP Price Action: Acurx Pharmaceuticals shares were down 12.95% at $5.24 during premarket trading on Thursday, according to Benzinga Pro data.

Image via Shutterstock